These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 16840427)

  • 1. Effect of dalbavancin on the normal intestinal microflora.
    Nord CE; Rasmanis G; Wahlund E
    J Antimicrob Chemother; 2006 Sep; 58(3):627-31. PubMed ID: 16840427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ceftaroline on normal human intestinal microflora.
    Panagiotidis G; Bäckström T; Asker-Hagelberg C; Jandourek A; Weintraub A; Nord CE
    Antimicrob Agents Chemother; 2010 May; 54(5):1811-4. PubMed ID: 20231399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of telavancin on human intestinal microflora.
    Rashid MU; Weintraub A; Nord CE
    Int J Antimicrob Agents; 2011 Dec; 38(6):474-9. PubMed ID: 21982049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ceftobiprole on the normal human intestinal microflora.
    Bäckström T; Panagiotidis G; Beck O; Asker-Hagelberg C; Rashid MU; Weintraub A; Nord CE
    Int J Antimicrob Agents; 2010 Dec; 36(6):537-41. PubMed ID: 20926263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tigecycline on normal oropharyngeal and intestinal microflora.
    Nord CE; Sillerström E; Wahlund E
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3375-80. PubMed ID: 17005820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ciprofloxacin in the human-flora-associated (HFA) rat model: comparison with the HFA mouse model.
    Perrin-Guyomard A; Poul JM; Laurentie M; Sanders P; Fernández AH; Bartholomew M
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):66-78. PubMed ID: 16563587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of dalbavancin against enterococci isolates from wild animals, pets, poultry and humans in Portugal.
    Poeta P; Radhouani H; Sargo R; Igrejas G
    J Basic Microbiol; 2008 Dec; 48(6):526-8. PubMed ID: 18798175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
    Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections.
    Edlund C; Nord CE
    J Antimicrob Chemother; 2000 Sep; 46 Suppl 1():41-8; discussion 63-5. PubMed ID: 11051623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecological impact of doxycycline at low dose on normal oropharyngeal and intestinal microflora.
    Rashid MU; Panagiotidis G; Bäckström T; Weintraub A; Nord CE
    Int J Antimicrob Agents; 2013 Apr; 41(4):352-7. PubMed ID: 23332619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.
    Bowker KE; Noel AR; MacGowan AP
    J Antimicrob Chemother; 2006 Oct; 58(4):802-5. PubMed ID: 16891629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora.
    Lode H; Von der Höh N; Ziege S; Borner K; Nord CE
    Scand J Infect Dis; 2001; 33(12):899-903. PubMed ID: 11868762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.